MARKET

MNPR

MNPR

Monopar Therapeutics Inc
NASDAQ
52.56
-1.54
-2.85%
Opening 11:30 03/30 EDT
OPEN
54.15
PREV CLOSE
54.10
HIGH
54.17
LOW
51.66
VOLUME
32.70K
TURNOVER
--
52 WEEK HIGH
105.00
52 WEEK LOW
26.06
MARKET CAP
351.74M
P/E (TTM)
-15.2915
1D
5D
1M
3M
1Y
5Y
1D
Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street
TipRanks · 14h ago
Monopar Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 16h ago
Monopar Therapeutics Price Target Maintained With a $100.00/Share by Chardan Capital
Dow Jones · 16h ago
Weekly Report: what happened at MNPR last week (0323-0327)?
Weekly Report · 17h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Kyverna Therapeutics, Inc. (KYTX) and Monopar Therapeutics Inc (MNPR)
TipRanks · 17h ago
Buy Rating Reaffirmed on ALXN1840 De‑Risking, 2027 Approval Potential, and Strong Cash Runway
TipRanks · 18h ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 20h ago
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16
Seeking Alpha · 3d ago
More
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Webull offers Monopar Therapeutics Inc stock information, including NASDAQ: MNPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNPR stock methods without spending real money on the virtual paper trading platform.